Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

An Open Trial to Assess the Tolerability of AVANZ Mite Mix Immunotherapy (AV-M-01)

This study has been completed.
Information provided by (Responsible Party):
ALK-Abelló A/S Identifier:
First received: March 29, 2012
Last updated: January 5, 2015
Last verified: January 2015
The purpose of the trial is to assess the tolerability of the up-dosing phase of AVANZ Mite mix.

Condition Intervention Phase
Allergic Rhinitis Due to Dust Mite
Biological: AVANZ MITE
Phase 2
Phase 3

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open Trial to Asses the Tolerability of AVANZ Mite Mix Immunotherapy

Further study details as provided by ALK-Abelló A/S:

Primary Outcome Measures:
  • Frequency of patients with adverse reactions. [ Time Frame: Participants wil be followed for an expected average of 6 weeks. ]
    From date of inclusion until date of last visit documented, it's expected an average of 6 visits, assessed up to 6 weeks per subject.

Secondary Outcome Measures:
  • Frequency of patients with systemic reactions according to EAACI classification [ Time Frame: Participants wil be followed for an expected average of 6 weeks. ]
    From date of inclusion until date of last visit documented, it's expected an average of 6 visits, assessed up to 6 weeks per subject.

Enrollment: 102
Study Start Date: December 2011
Study Completion Date: July 2012
Primary Completion Date: July 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: AVANZ
Biological: AVANZ MITE
Immunotherapy Dermatophagoides mix

Detailed Description:
The frequency of patients with adverse reactions will be the primary endpoint.

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male and female patients 18-65 years of age.
  • A clinical history of HDM induced allergic rhinoconjunctivitis with or without asthma at least one year prior to trial entry.
  • Positive SPT to Dermatophagoides pteronyssinus (Der pte) or Dermatophagoides farinae (Der far) (wheal diameter ≥ 3 mm).
  • A positive specific IgE against Der pte or Der far (≥Class 2; ≥0.70 KU/L) documenting in the last 5 years.

Exclusion Criteria:

  • FEV1 < 70% of predicted value at screening after adequate pharmacologic treatment.
  • Uncontrolled or severe asthma.
  • A clinically relevant history of symptomatic perennial allergic rhinitis and/or conjunctivitis caused by an allergen, to which the subject is regularly exposed and sensitized.
  • History of severe asthma exacerbation or emergency room visit or admission for asthma in the previous 12 months.
  • At screening, current symptoms of, or treatment for, upper respiratory tract infection, acute sinusitis, acute otitis media or other relevant infection (serous otitis media is not an exclusion criterion).
  • Treatment with parenteral corticosteroids, oral corticosteroids or anti-IgE in the previous 3 months or during the study (except for steroids if needed as rescue medication). Please, see Table 4.
  • Currently treated with angiotensin converting enzyme (ACE) inhibitors, tricyclic antidepressants, β-blockers, mono amine oxidase inhibitors (MAOIs) and any other drug containing alum (e.g. antacids) taken on a daily basis.
  • Previous treatment by other allergen concomitant IT or immunotherapy with HDM extracts within the previous 5 years (initiation of subcutaneous immunotherapy is acceptable if treatment has been discontinued before reaching maintenance dose; for SLIT 3 months in the last 5 years is accepted).
  • History of anaphylactic shock due to e.g. food, insect venom, exercise or drug.
  • History of severe and recurrent angioedema.
  • Any contraindication according to the Investigator Brochure (IB).
  • Use of an investigational drug within 30 days prior to screening.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01568190

Hospital Virgen Del Camino
Pamplona, Navarra, Spain, 31008
Sponsors and Collaborators
ALK-Abelló A/S
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: ALK-Abelló A/S Identifier: NCT01568190     History of Changes
Other Study ID Numbers: 2011-002017-11
2011-002017-11 ( EudraCT Number )
Study First Received: March 29, 2012
Last Updated: January 5, 2015

Keywords provided by ALK-Abelló A/S:
House dust mites sensitisation

Additional relevant MeSH terms:
Rhinitis, Allergic
Nose Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Otorhinolaryngologic Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases processed this record on May 25, 2017